Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):988-990; doi:10.1093/jnci/djm057
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/13/988    most recent
djm057v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twombly, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Small Study on Industry Trial Sponsorship Leads to Big Questions About Quality and Bias

Renee Twombly

The first 150 words of the full text of this article appear below.

Pharmaceutical industry support has far surpassed federal funding for clinical research in the United States. And many drugs currently under development are designed by the industry to fight cancer. So researchers at the University of North Carolina School of Medicine and Dana-Farber Cancer Institute undertook a small project to see if there was any association between pharmaceutical company involvement and outcomes in breast cancer clinical trials. It was the only study of its kind conducted in breast cancer research and only the second on any type of cancer.

Published in April in Cancer, the paper looked at 140 studies conducted in 1993, 1998, and 2003—arbitrarily chosen 5-year spans—and found no statistically significant difference between positive outcomes and industry versus nonindustry authorship (78% versus 66%). But when they focused on the 56 studies published in 2003, when disclosure requirements were the tightest, they found that 84% of studies reporting pharmaceutical . . . [Full Text of this Article]

Searching for Bias

Registries Provide Clues


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?